Jump to content

AstraZeneca share price rebounds following FY21 results update


Recommended Posts

In this article we review the AstraZeneca results and how the share price has reacted to the news.

bg_astrazeneca_336609093.jpgSource: Bloomberg
 Shaun Murison | Senior Market Analyst, Johannesburg | Publication date: Thursday 10 February 2022 

AstraZeneca's fourth quarter (Q4) and full-year (FY) results have seen the group’s share price bucking the short-term sector trend as of late as it gains on the news.

A summary of the results is as follows:

  • Total revenue for the year increased by 41% to $37,417 million including COVID-19 vaccine revenues
  • Total Revenue for the year, excluding vaccines, increased 26% to $33,436m
  • Reported earnings per share (EPS) of $0.08 in FY21 vs $2.44 in FY20
  • Core EPS of $5.29 in FY21 vs $4.02 in FY20

FY22 outlook

AstraZeneca has provided the following in terms of the new financial year's outlook:

  • The majority of vaccine revenue in 2022 is expected to come from initial contracts
  • The Gross Profit Margin from the COVID-19 medicines is expected to be lower than the company average
  • Core Operating Expenses are expected to increase by a low-to-mid teens percentage, driven in substantial part by the full-year integration of Alexion expenses
  • Emerging Markets Total Revenue, including China, is expected to grow mid-single digits in FY 2022
  • China Total Revenue is expected to decline by a mid-single digit percentage in FY 2022, primarily due to continued NRDL and VBP programme impacting various medicines
  • The company remains confident in the longer term outlook for Emerging Markets, driven by a large market opportunity, broader patient access and an increased mix of new medicines

Comments on results

Double-digit growth across all of the group’s major jurisdictions, combined with the Alexion acquisition, has seen strong revenue growth for the group.

The reported drop in EPS (97%) reflects items related to the acquisition of Alexion, amortisation of intangibles, as well as impairments and restructuring charges.

The Core EPS figure, which omits the one-off items, highlights growth of around 32% in the group's primary operations.

While future earnings growth from COVID-19 products is expected to slow, the group is perhaps less reliant on these products than its peers, Pfizer and Moderna as a proportion of income and future growth.

Astrazeneca – technical analysis

AZ%201002.pngSource: IG charts

 

The share price of AstraZeneca has formed a sharp bullish price reversal near the 8120 level and from oversold territory. The reversal suggests 8860 and 8960 respectively as upside resistance targets from the move.

Traders looking to go long might consider using a close below 8120 as a stop-loss indication for the trade, although will need to assess whether the risk-to-reward is a favourable enough opportunity for the position.

Link to comment

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • General Statistics

    • Total Topics
      20,124
    • Total Posts
      88,217
    • Total Members
      69,105
    • Most Online
      7,522
      10/06/21 10:53

    Newest Member
    Amur3001
    Joined 05/10/22 18:59
  • Posts

    • Market data to trade on Thursday: Aussie Trade; Levi earnings With the upside risk for forecasts for the Australian trade data, IGTV’s Jeremy Naylor looks at the long trade on the Aussie benchmark, the S&P ASX 200. Earnings out on Thursday include Constellation Brands and Levi Strauss.      
    • Dear All, On the September 22 I could not sell Presto automation stock $PRST.  I have reported that to IG helpdesk, had multiple calls etc. It is not obvious where this process is going and I need my refund money ASAP. I have sent the screenshots etc.
    • Hi @Adnan_The_Barbarian Unfortunately we do not offer GDR's (Global Depository Receipt) for share dealing.   All the best - MongiIG 
×
×
  • Create New...